The challenges of the pandemic have been particularly acute for transplant recipients. As vaccination programs begin rolling out across the country, there remain many unanswered research questions about COVID-19 vaccination in this population, who were excluded from all of the initial clinical trials. Over the last few months, CDTRP has been working to connect, mobilize, and align our community to identify and address these urgent issues.
These discussions culminated in a large national research proposal (PRospective Evaluation of COVID-19 Vaccine in Transplant Recipients (PREVenT-COVID
): A National Strategy) submitted to the COVID-19 Immunity Task Force
(CITF) for funding. Research teams in Vancouver, Edmonton, London, Toronto, Montreal, and Quebec City, through a collaboration led by Dr. Deepali Kumar (University Health Network) and supported by the CDTRP network infrastructure, proposed a set of immunogenicity studies and a national safety surveillance study in transplant recipients.
The national safety surveillance study will be conducted in partnership with the Canadian National Vaccine Safety (CANVAS). CANVAS is monitoring COVID-19 safety in the general public across Canada, with different regional approaches to recruitment, and a standardized set of REB-approved questionnaires.
You can download all the workshop reports below.